152 related articles for article (PubMed ID: 22393083)
1. Estrogen receptor in breast ductal carcinoma in situ: good cop, bad cop?
DeCensi A; Pruneri G; Guerrieri-Gonzaga A
J Clin Oncol; 2012 Apr; 30(12):1384-6. PubMed ID: 22393083
[No Abstract] [Full Text] [Related]
2. [Breast ductal carcinoma in situ with microinvasion: pathological review and clinical implications].
Modesto A; Gandy C; Mery E; Filleron T; Massabeau C; Izar F; Charitansky H; Roché H; de Lafontan B
Cancer Radiother; 2014 Mar; 18(2):107-10. PubMed ID: 24637020
[TBL] [Abstract][Full Text] [Related]
3. The receptor expression pattern in ductal carcinoma in situ predicts recurrence.
Kepple J; Henry-Tillman RS; Klimberg VS; Layeeque R; Siegel E; Westbrook K; Korourian S
Am J Surg; 2006 Jul; 192(1):68-71. PubMed ID: 16769278
[TBL] [Abstract][Full Text] [Related]
4. Triple-negative breast cancers: unique clinical presentations and outcomes.
Billar JA; Dueck AC; Stucky CC; Gray RJ; Wasif N; Northfelt DW; McCullough AE; Pockaj BA
Ann Surg Oncol; 2010 Oct; 17 Suppl 3():384-90. PubMed ID: 20853062
[TBL] [Abstract][Full Text] [Related]
5. Molecular markers and therapeutic targets in ductal carcinoma in situ.
Boland GP; Knox WF; Bundred NJ
Microsc Res Tech; 2002 Oct; 59(1):3-11. PubMed ID: 12242692
[TBL] [Abstract][Full Text] [Related]
6. Management of in situ carcinoma of the breast: lobular and ductal origin.
White RE; Bland KI
R I Med; 1995 Sep; 78(9):242-5. PubMed ID: 7579718
[No Abstract] [Full Text] [Related]
7. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet?
Schnitt SJ; Harris JR; Smith BL
Cancer; 1996 Jun; 77(11):2189-92. PubMed ID: 8635082
[No Abstract] [Full Text] [Related]
8. An unusual triple-negative breast carcinoma.
Shousha S; Peston D; Gojis O; Palmieri C
Histopathology; 2009 Sep; 55(3):364-6. PubMed ID: 19723156
[No Abstract] [Full Text] [Related]
9. The estrogen receptors alpha, beta, and beta cx.
Shaaban AM; Speirs V
Clin Cancer Res; 2005 Nov; 11(22):8222; author reply 8222-3. PubMed ID: 16299256
[No Abstract] [Full Text] [Related]
10. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. Seventh International Conference on Adjuvant Therapy of Primary Breast Cancer.
Goldhirsch A; Glick JH; Gelber RD; Coates AS; Senn HJ
J Clin Oncol; 2001 Sep; 19(18):3817-27. PubMed ID: 11559719
[No Abstract] [Full Text] [Related]
11. Prognostic significance of selected immunohistochemical parameters in patients with invasive breast carcinoma concomitant with ductal carcinoma in situ.
Patla A; Rudnicka-Sosin L; Pawlega J; Stachura J
Pol J Pathol; 2002; 53(1):25-7. PubMed ID: 12014222
[TBL] [Abstract][Full Text] [Related]
12. [Clinicopathological characteristics and prognostic factors of breast cancer with estrogen- and progesterone-receptor negative and HER-2 overexpression].
Fan Y; Guan Y; Zhao WH; Li Q; Xu BH
Zhonghua Zhong Liu Za Zhi; 2008 Dec; 30(12):917-20. PubMed ID: 19173993
[TBL] [Abstract][Full Text] [Related]
13. Correlated expression of erbB-3 with hormone receptor expression and favorable clinical outcome in invasive ductal carcinomas of the breast.
Lee Y; Cho S; Seo JH; Shin BK; Kim HK; Kim I; Kim A
Am J Clin Pathol; 2007 Dec; 128(6):1041-9. PubMed ID: 18024331
[TBL] [Abstract][Full Text] [Related]
14. Developing a prognostic index for ductal carcinoma in situ of the breast. Are we there yet?
Silverstein MJ; Craig PH; Lagios MD; Waisman JK; Lewinsky BS; Colburn WJ; Poller DN
Cancer; 1996 Sep; 78(5):1138-40. PubMed ID: 8780555
[No Abstract] [Full Text] [Related]
15. The presence of alveolar structures in invasive ductal NOS breast carcinoma is associated with lymph node metastasis.
Zavyalova MV; Perelmuter VM; Vtorushin SV; Denisov EV; Litvyakov NV; Slonimskaya EM; Cherdyntseva NV
Diagn Cytopathol; 2013 Mar; 41(3):279-82. PubMed ID: 22102485
[No Abstract] [Full Text] [Related]
16. Invasive ductal carcinoma of the breast with the "triple-negative" phenotype: prognostic implications of EGFR immunoreactivity.
Viale G; Rotmensz N; Maisonneuve P; Bottiglieri L; Montagna E; Luini A; Veronesi P; Intra M; Torrisi R; Cardillo A; Campagnoli E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2009 Jul; 116(2):317-28. PubMed ID: 18839307
[TBL] [Abstract][Full Text] [Related]
17. Microinvasive (T1mic) lobular carcinoma of the breast: clinicopathologic profile of 16 cases.
Ross DS; Hoda SA
Am J Surg Pathol; 2011 May; 35(5):750-6. PubMed ID: 21415700
[TBL] [Abstract][Full Text] [Related]
18. Hormone receptor status and survival in a population-based cohort of patients with breast carcinoma.
Grann VR; Troxel AB; Zojwalla NJ; Jacobson JS; Hershman D; Neugut AI
Cancer; 2005 Jun; 103(11):2241-51. PubMed ID: 15844176
[TBL] [Abstract][Full Text] [Related]
19. Expression of c-erbB2, cyclin D1 and estrogen receptor and their clinical implications in the invasive ductal carcinoma of the breast.
Lee A; Park WC; Yim HW; Lee MA; Park G; Lee KY
Jpn J Clin Oncol; 2007 Sep; 37(9):708-14. PubMed ID: 17940078
[TBL] [Abstract][Full Text] [Related]
20. Vimentin expression does not assist in predicting survival in ductal carcinoma of the breast.
Heatley MK; Ewings P; Odling Smee W; Maxwell P; Toner PG
Pathology; 2002 Jun; 34(3):230-2. PubMed ID: 12109782
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
